Conversion Disorder Clinical Trial
Official title:
Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Verified date | August 2023 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Functional Neurological Disorder (FND/ Conversion Disorder) is a highly prevalent and disabling neuropsychiatric condition. Motor FND symptoms include Nonepileptic Seizures, Functional Movement Disorders and Functional Weakness. Clinical research across these motor FND subtypes, including research studies from the candidate's laboratory, suggest that these populations share many clinical and phenotypic similarities that warrant increased research integration. Furthermore, despite the prevalence of motor FND, little is known about the underlying pathophysiology of this condition, which is a prerequisite for the development of biologically informed prognostic and treatment response biomarkers. Across 3 published neurobiologically focused articles, the candidate proposed a framework through which to conceptualize motor FND. It is suggested that motor FND develops in the context of structural and functional alterations in neurocircuits mediating emotion awareness/expression, bodily awareness, viscerosomatic processing and behavioral regulation. The overall goal of this project is to comprehensively investigate structural and functional magnetic resonance imaging (MRI) biomarkers of prognosis across motor FND. Multimodal structural and functional MRI techniques (including voxel-based morphometry, cortical thickness, resting-state functional connectivity and diffusion tensor imaging tractography) will be used to systemically probe brain-prognosis relationships. Novel aspects of this proposal include the study of the full spectrum of motor FND, consistent with a trans-diagnostic approach.
Status | Completed |
Enrollment | 30 |
Est. completion date | January 20, 2023 |
Est. primary completion date | January 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - clinically established motor functional neurological disorder, including individuals with functional movement disorders, functional limb weakness and psychogenic nonepileptic seizures Exclusion Criteria: - active suicidality - major medical/neurological comorbidities with known central nervous system (CNS) consequences - active drug use or alcohol dependence - known history of a primary psychotic disorder |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Diez I, Ortiz-Teran L, Williams B, Jalilianhasanpour R, Ospina JP, Dickerson BC, Keshavan MS, LaFrance WC Jr, Sepulcre J, Perez DL. Corticolimbic fast-tracking: enhanced multimodal integration in functional neurological disorder. J Neurol Neurosurg Psychi — View Citation
Perez DL, Williams B, Matin N, Mello J, Dickerson BC, LaFrance WC Jr, Keshavan MS. Anterior hippocampal grey matter predicts mental health outcome in functional neurological disorders: an exploratory pilot study. J Neurol Neurosurg Psychiatry. 2018 Nov;89 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison | Correcting for multiple comparisons in structural analyses, baseline structural grey matter volumes in limbic/paralimbic regions (particularly those affiliated with the salience network), would relate to clinical outcome in individuals receiving the standard of care at 6 months. Analyses reported refer to change in either mental health or physical health scores and baseline gray matter volume. The number presented is the peak voxel z-score as also reported in Supplementary Table 4 of the published manuscript.
Z-scores are presented in absolute values (with the lowest value being 0). A higher z-score represents a stronger correlation between a given gray matter volume value (at the peak voxel) and the measure of interest (in case mental health or physical health scores). The entry under "row title" specifies if the association is a "positive" vs a "negative" association. |
baseline and 6 months | |
Primary | Resting State Functional Connectivity Strength Biomarkers of 6 Month Prognosis - Within Group Comparison | Correcting for multiple comparisons in resting state connectivity analyses, baseline functional connectivity strength (t-statistic scores) across limbic/paralimbic regions (particularly those affiliated with the salience network), would relate to clinical outcome in individuals receiving the standard of care at 6 months. Here, we tested if link-step connectivity from primary motor areas or amygdala nuclei related to change in clinical outcome. Specifically, we are providing the t-statistic for the connectivity strength between left centromedial amygdala to right anterior insula.
Functional connectivity strength is based on the correlation of low frequency brain oscillations measured at rest. A large t-statistic value reflects greater connectivity between brain voxels. |
baseline and 6 months | |
Primary | The Integrity of Specific White Matter Tracts (Fractional Anisotropy) as Measured by Diffusion Tensor Imaging (DTI) Tractography Will Relate to 6-month Prognosis | Baseline integrity of the cingulum bundle and cingulate-insular tracts, as measured by fractional anisotropy, would relate to 6 month prognosis in patients with Functional Neurological Disorders (FND) receiving the standard of care.
Outcome was not assessed - no time to analyze data given prior challenges with the pandemic. Unable to report data in any table as the white matter images have not been analyzed. |
baseline and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02275000 -
Feasibility Study of Physiotherapy for Functional Motor Symptoms
|
N/A | |
Completed |
NCT00971360 -
Cytokine Levels in Conversion Disorder
|
N/A | |
Completed |
NCT00835627 -
Treatment Trial for Psychogenic Nonepileptic Seizures
|
Phase 4 | |
Active, not recruiting |
NCT01422278 -
Rehabilitation of Conversion Gait Disorder
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03441867 -
Neuroimaging Biomarker for Seizures
|
N/A | |
Completed |
NCT02102906 -
TMS and Attentional Bias in Functional Motor Disorder
|
N/A | |
Completed |
NCT02325544 -
Comparing Different Treatments in Reducing Dissociative Seizure Occurrence
|
N/A | |
Terminated |
NCT02764476 -
Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder
|
N/A | |
Recruiting |
NCT05323344 -
Metacognitive Therapy and Neuro-physiotherapy as a Treatment for Functional Movement Disorders
|
N/A | |
Recruiting |
NCT04097184 -
Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients
|
N/A | |
Completed |
NCT05219006 -
Ketogenic Diet Effects on the Frequency of Non Epileptic Seizures
|
N/A | |
Completed |
NCT02329626 -
Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
|
||
Recruiting |
NCT05943652 -
Observational Study on "Functional Overlay" in Patients With Movement Disorders
|
||
Completed |
NCT00159965 -
Treatments for Psychogenic Nonepileptic Seizures (NES)
|
Phase 4 | |
Completed |
NCT05305014 -
Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder
|